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Abstract 19 
The limited availability of drugs registered for dairy goats makes veterinarians 20 
prescribe off-label treatments with a legally established minimum safety period of seven 21 
days. The aim of this work was to verify if the exceptional use of macrolide antibiotics in 22 
dairy goats generates residues in milk and cheeses within that period. Hence, three 23 
macrolide drugs (erythromycin, tylosin and spiramycin) were administred in an in vivo 24 
experiment in dairy goats. Ripened cheeses were made from bulk milk obtained before 25 
drug administration, 24 hours after treatment, and at the end of the recommended 26 
withdrawal period. Residual amounts of erythromycin (234.9±52.7 µg/kg), tylosin 27 
(198.7±57.8 µg/kg) and spiramycin (1,539.8±469.4 µg/kg), widely exceeding their legal 28 
maximum residue limits (MRLs) established, were detected in milk collected 24 hours 29 
after treatment, making the cheese production in most cases impossible. After the seven-30 
day period, only spiramycin was detected in goat’s milk (79.6±19.2 µg/kg) although no 31 
antibiotic residues were found in the cheeses. A withdrawal time of seven days seems 32 
suitable to guarantee milk safety after the administration of erythromycin and tylosin 33 
without any negative effects neither on the milk nor on the and cheese properties. 34 
However, given the rapid elimination of these substances, a shorter withdrawal period 35 
might be considered. For spiramycin, persisting in milk for a longer period, further studies 36 
on its pharmacokinetics in dairy goats would be recommendable to avoid a potential risk 37 
to consumer health. 38 
 39 
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1. Introduction 41 
Antibiotic therapy plays an important role in dairy livestock health and consequently 42 
in milk production. In dairy goats, antibiotics are usually applied to treat mastitis and 43 
other infectious diseases. However, it should be noted that due to the low volume of 44 
business which milk production from small ruminants represents, in comparison to cow 45 
milk, there is evidently a limited availability of drugs registered for these species leading 46 
veterinarians to employ unregistered drugs. Although the exceptional use of such drugs 47 
is legally considered (European Parliament and the Council of the European Union, 2001; 48 
European Parliament and the Council of the European Union, 2004), the risk of drug 49 
residues in milk and dairy products might increase as the required elimination period is 50 
not always known. In this sense, studies carried out in dairy goats (Ferrini et al., 2010; 51 
Amer et al., 2012) showed that the minimum withdrawal period of seven days laid down 52 
in legislation for off-label treatments is not always sufficient to ensure the absence of drug 53 
residues in milk. It should be noted that the presence of antibiotic residues in milk may 54 
have negative implications for consumer health, causing transient disturbances in the 55 
intestinal flora and allergic reactions which can, in extreme cases, lead to anaphylaxis 56 
(Graham et al., 2014). Also, there is concern that the development of bioresistance may 57 
be caused by such residues (EFSA, 2016). Finally, the bacterial processes required for the 58 
elaboration of fermented products such as cheeses and yoghurt may be inhibited by such 59 
residues (Berruga et al., 2008; Cabizza et al., 2017), an important aspect when considering 60 
that goat’s milk is primarily intended for cheese-making. 61 
Respect at the use of veterinary drug  Spain is the second country after United 62 
Kingdom, which has used the most antimicrobial agents for goats and sheep species. In 63 
addition, among the sales of antimicrobial agents for food-producing species, the 64 
macrolides constitute the fourth most important group of antimicrobials applied, behind 65 
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the tetracyclines, penicillins and sulfonamides (EMA, 2017). Macrolides are antibacterial 66 
compounds usually applied in veterinary medicine showing in vitro activity against a 67 
wide range of pathogenic microorganisms including mycoplasma, Gram positive 68 
bacteria, and some Gram negative bacteria like Pasteurella spp. (Clothier et al., 2012). 69 
The antibacterial activity of such drugs is based on the inhibition of bacterial protein 70 
synthesis by binding to bacterial 50S ribosomal subunits (Papich and Riviere, 2001). 71 
Macrolides may also have an immune-modulating effect on cell-mediated immunity (Cao 72 
et al., 2006). 73 
In dairy goats, macrolides are usually employed in an off-label manner to treat 74 
respiratory conditions, and mastitis (Atef et al., 2009; Young et al., 2011), as well as 75 
contagious agalactia in endemic areas (Gómez-Martín et al., 2013).  76 
Systemically administered macrolides are distributed through the udder tissues and 77 
milk, reaching concentrations higher than those measured in plasma (Al-Wabel, 2008; 78 
Avci and Elmas, 2014). Xenobiotics cross the blood–milk barrier by passive diffusion, 79 
thus, the basic nature of macrolides (pKa values ranging 6-9) and their low degree of 80 
ionization (18-30 %) favour their trapping in the udder, as milk has a lower pH than blood 81 
(Ambros et al., 2007).  82 
Studies have been performed to evaluate the pharmacokinetics of macrolides in tissues 83 
and plasma of some animal species including goats (Taha et al., 1999; Cárceles et al., 84 
2005). However, very little information is available on residual patterns of macrolides in 85 
goat’s milk with excretion times ranging from a few hours to several days (Ambros et al., 86 
2007; Amer et al., 2012). The aim of this work was: 1) to verify if the exceptional use of 87 
macrolide antibiotics in dairy goats leads to residues in milk and cheese, thus posing a 88 
risk for consumer health, and 2) to evaluate the effect of these treatments on cheese 89 
manufacturing and the characteristics of matured cheeses. 90 
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2. Material and Methods 92 
Experimental procedure 93 
The study was carried out with the experimental herd of Murciano-Granadina goats of 94 
Institute of Animal Science and Technology at Universitat Politècnica de València (UPV, 95 
Valencia, Spain). Animal management protocols were approved by the Ethics Committee 96 
of UPV. 97 
For each antibiotic treatment, 24 healthy goats were used, each weighing 45-55 kg, 98 
randomly allocated in two groups (2x12), being in mid-lactation and not having received 99 
any veterinary drug prior to the experiment. Machine-milking was carried out once a day 100 
in the morning (08:00 a.m.). 101 
Three macrolide antibiotics (erythromycin, tylosin and spiramycin) registered for the 102 
use in cattle and pigs, were selected for this study. All the treatments were administrated 103 
after morning milking by the intramuscular route. The veterinary drugs used were: 104 
Pantoyet® (Laboratorios Syva, S.A. León, Spain), 200 mg/mL of erythromycin, dose: 0.5 105 
mL/10 kg body weight on three consecutive days; Trelacón® (Laboratorios Elanco 106 
Valquímica, S.A. Madrid, Spain), 200 mg/mL of tylosin, dose: 0.5 mL/10 kg body weight 107 
on three consecutive days; and Mycogal® (Laboratorios Ovejero, S.A. León, Spain), 108 
276.3 mg (1.05 MUI)/mL of spiramycin, dose: 1 mL/10 kg body weight in a single dose. 109 
The withdrawal period considered was seven days after the last drug administration, as 110 
stipulated by European legislation for the exceptional use of antibiotics, except for 111 
Mycogal® (spiramycin) for which two withdrawal times (seven and 14 days) were 112 
considered as the manufacturer’s specification sheet indicates a withdrawal period (11 113 
days) for dairy cows. During the experimental period, bulk milk samples (50 mL) were 114 
taken on a daily basis to detect the presence of drug residues. 115 
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Different cheese making trials of ripened cheese were made for each experimental 116 
animal group: one day before the antibiotic treatment was applied (pre-treatment cheeses: 117 
PT-cheeses, which were then used as reference), 24 hours thereafter (after treatment 118 
cheeses: AT-cheeses), and after the safety period of seven days, in the case of spiramycin 119 
adicional cheese-making after withdrawal of 14 days. (after withdrawal period cheeses: 120 
AW-cheeses). Therefore, it supposes a total of six cheese-making for each one of the 121 
substances tested except for spiramycin, which were eight manufactures. In all cases, bulk 122 
milk samples (100 mL) were analysed prior to the cheese production. 123 
Immediately after the milking had taken place, the cheese was made at the UPV pilot 124 
plant, following the artisanal making-process for mature Tronchón cheese. A vat of raw 125 
bulk milk was inoculated with mesophilic starter cultures (Choozit MA4001, Danisco, 126 
Paris, France), and heated to 32±1 ºC. Then, calcium chloride (Proquical, Proquiga, A 127 
Coruña, Spain) and calf rennet (Suministros Arroyo, Santander, Spain) were added at 128 
0.013 % (v/v) and 0.07 % (v/v), respectively. After the coagulation (30-40 min), the curd 129 
was cut and scalded (33-35 ºC) whilst being stirred for 90-100 min. The curds were 130 
moulded, pressed for 3.5 h, and salted by immersion in brine (23% w/v). The cheeses 131 
ripened for a 60-day period and the cheese sample analysis was carried out at the 132 
beginning and the end of the ripening period, using one piece of cheese from each of the 133 
cheese-making and ripening times considered. 134 
Milk Analysis 135 
Milk samples were analysed by MilkoScan 6000 (Foss, Hillerd, Denmark) to 136 
determine the chemical composition (fat, protein and total solids); somatic cell count 137 
(SCC) and total bacterial count (TBC) were obtained using Fossomatic 5000 (Foss) and 138 
Bactoscan FC (Foss), respectively. The milk pH value was measured by a conventional 139 
pH-meter (model Basic 20, Crison, Barcelona, Spain).  140 
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Cheese Analysis 141 
The kinetic acidification of the milk curd was checked periodically during cheese-142 
making using a pH-meter (model Basic 20, Crison, Barcelona, Spain) with a penetration 143 
probe (model 5232, Crison, Barcelona, Spain). 144 
Cheese samples were characterized twice whilst ripening (1 and 60 days) by assessing 145 
quality variables such as acidity, water activity (aw), free fatty acids (FFA) and free amino 146 
acids (FAA) contents. 147 
The pH value of the cheese samples was measured in duplicate using a pH-meter with 148 
a penetration probe (model 5232, Crison, Barcelona, Spain). A dew point hygrometer 149 
(Decagon Devices Inc., Aqualab 4TE, Pullman, Washington, USA) was employed to 150 
determine the water activity (aw) making two replicate analysis.  151 
The FFA concentration (meq/100 g of fat) and the FFA content (mg of leucine/g of 152 
cheese) were determined in duplicate according to the methodologies described by Nuñez 153 
et al., (1986) and Folkertsma and Fox, (1992), respectively.  154 
Textural and colour properties were made in triplicate using circular samples (20 mm 155 
in diameter and 10 mm in height) obtained from an intermediate area between the rind 156 
and the center of the cheese. A Texture Profile Analysis (TPA) was carried out using TA-157 
XT Plus Texture Analyser (Stable Micro Systems, Surrey, UK) equipped with a cylinder 158 
probe of 45 mm diameter (P/45). The cheese sample was compressed to 50 % of its height 159 
in two sequential compression events (constant deformation rate of 1 mm s−1) separated 160 
by a rest phase of 5 s.The colour coordinates CIE L*, a* and b* were obtained employing 161 
a spectrocolorimeter (model CM-3600D, Minolta, Tokyo, Japan) using observer 10º and 162 
illuminant D65. 163 
Antibiotic residues analysis 164 
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Antibiotic residues in goat’s milk and cheeses were analysed at the Instituto 165 
Lactológico de Lekunberri (Pamplona, Spain) using a liquid chromatography tandem 166 
mass spectrometry (LC-MS/MS) technique. For chromatographic analysis, an Alliance 167 
2695 high-performance liquid chromatograph with a diode-array detector from Waters 168 
(Waters Chromatography Division, Milford, MA, USA) was employed. Separation of 169 
compounds was accomplished using an XBridgeTM C18 column (Waters 170 
Chromatography Division). Mass spectral analyses were performed on a Micromass 171 
Quattro MicroTM triple quadrupole tandem mass spectrometer (Waters Chromatography 172 
Division). The calibration curves had previously been established for each macrolide 173 
considered; the quantification limit (LOQ) being equal to 10 µg/kg for tylosin and 174 
erythromycin, and 30 µg/kg for spiramycin. MassLynx 4.0 software (Waters) was used 175 
to calculate the macrolide concentrations in goat’s milk and cheeses. 176 
Statistical analysis 177 
Statgraphics Centurion XVI.II (Statpoint Technologies, Inc. The Plains, Virginia, 178 
USA) was used for the statistical analysis. The milk quality variables were analyzed using 179 
a multifactorial ANOVA including the effects of the Milk sampling (PT: pre-treatment, 180 
AT: 24 hours after treatment, and AW: after the withdrawal period) and the animal group 181 
(1 to 2). 182 
In cheeses, multifactorial ANOVA was applied to study the influence of the different 183 
factors considered according to the model: 184 
𝑌𝑖𝑗𝑘𝑙 =  µ + 𝐶𝑖 + 𝑅𝑗 + 𝐺𝑘 + (𝐶𝑖 × 𝑅𝑗) + (𝐶𝑖 × 𝐺𝑘) + (𝑅𝑗 × 𝐺𝑘) + 𝑒𝑖𝑗𝑘𝑙  185 
where: 𝑌𝑖𝑗𝑘𝑙= dependent variable; µ= mean; 𝐶𝑖= cheese-making (PT: pre-treatment, AT: 186 
24 hours after treatment, and AW: after the withdrawal period); 𝑅𝑗= ripening time (1 or 187 
60 days); 𝐺𝑘= animal group (1 or 2). 𝐶𝑖 × 𝑅𝑗 = Effect of interaction cheese-making and 188 
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ripening time; 𝐶𝑖 × 𝐺𝑘 = effect of interaction cheese-making and animal group; 𝑅𝑗 × 𝐺𝑘= 189 
effect of interaction ripening time and animal group; 𝑒𝑖𝑗𝑘𝑙= residual error. 190 
In both analyses, multiple comparisons of the mean values were made using the LSD 191 
test (least significant difference) with a significance level of α= 0.05. 192 
3. Results 193 
The off-label use of erythromycin, tylosin, and spiramycin in dairy goats under 194 
conditions described in this study had no significant effect (p>0.05) on the milk quality 195 
parameters such as gross composition, pH, SCC, and TBC. In all cases, similar 196 
characteristics were observed in bulk milk obtained before drug administration as well as 197 
in the milk collected 24 hours after treatment, and at the end of the withdrawal period 198 
considered for each antibiotic. The mean values for gross composition (g/100 g) of raw 199 
milk used for cheese manufacture were as follows: 14.40±0.40 for total solids, 5.30±0.29 200 
for fat, and 3.74±0.18 for protein. The pH-value was 6.72±0.05, SCC 707,800 cells/mL, 201 
and TBC 21,900 cfu/mL. However, residues of erythromycin (234.9±52.7 µg/kg), tylosin 202 
(198.7±57.8 µg/kg) and spiramycin (1539.8±469.4 µg/kg) were found in goat’s milk 24 203 
hours after the last drug administration. In all cases, the residues decreased markedly 204 
along time becoming undetectable in milk 3-5 days after completing antibiotic therapy, 205 
except for spiramycin, whose residues were quantified in milk until the eighth day of the 206 
withdrawal period (Fig. 1). 207 
Regarding cheeses, the residual amounts of erythromycin and spiramycin in bulk milk 208 
collected on the first day post-treatment inhibited the starter-culture activities, thus 209 
impeding the acidification process necessary for the cheeses to reach their final pH of 5.3 210 
required for maturation. Therefore, the manufacturing of AT-cheeses due to these 211 
substances was not feasible. 212 
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However, cheese-making remained unaffected (p>0.05) by the presence of tylosin 213 
above the safety limits in milk from treated goats (198.7±57.8 µg/kg), although residual 214 
amounts of this substance were detected in cheeses along the entire ripening period. Thus, 215 
the tylosin concentration in AT-cheeses at the beginning of maturation was 178.9±3.3 216 
µg/kg which decreased significantly along time reaching a final concentration of 86.8±4.7 217 
µ/kg at 60 days of ripening. 218 
On the other hand, the cheese-making from goat’s milk obtained after the legally 219 
established minimum withdrawal period, seven days, remained unaffected by the 220 
antibiotic treatment applied (p>0.05), even for goat’s milk containing residual amounts 221 
of spiramycin (79.6±19.2 µg/kg) which was not detected in cheeses, regardless of the 222 
ripening time considered. 223 
The characteristics of ripened Tronchón cheeses produced in this study after the off-224 
label use of erythromycin, tylosin and spiramycin are presented in Tables 1, 2, and 3, 225 
respectively. 226 
As shown in Table 1, the cheeses made from bulk milk obtained seven days after the 227 
last administration of erythromycin showed similar characteristics to cheeses produced 228 
before the antibiotic treatment (p>0.05). These results were observed in the two 229 
experimental goats group performed (p>0.05) with the cheese properties being only 230 
affected by the maturation period (P<0.001) leading to lower cohesiveness, chewiness 231 
and water activity values as well as higher concentrations of FFA and FAA at 60 days of 232 
maturation. None of the interactions considered in the statistical model affected the 233 
quality variables studied (P>0.05). 234 
Results for the antibiotic treatment with tylosin (Table 2) indicate that cheeses made 235 
from milk after the last drug administration (AT-cheeses) showed higher hardness values 236 
(P<0.05) and a lower FAA concentration (P<0.01) than the other two types of cheese. As 237 
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shown in Fig. 2, statistical differences in the FAA concentration were only detected at the 238 
end of the 60-day ripening period (interaction 𝐶𝑖 × 𝑅𝑗 , P<0.05) evidencing a lower 239 
proteolytic activity in the AT-cheeses during maturation. On the other hand, both lower 240 
lipolytic and proteolytic activities were also observed in cheeses made in the second 241 
experimental replicate (P<0.05) although the related interactions (𝐶𝑖 × 𝐺𝑘 and  𝑅𝑗 × 𝐺𝑘) 242 
were non-significant. 243 
Regarding spiramycin, it should be noted that the characteristics of cheeses made prior 244 
to drug administration (PT-cheeses) did not differ significantly (P>0.05) from those of 245 
the cheeses manufactured after the antibiotic treatment (Table 3).  It has not had a 246 
significant effect on the characteristics of the cheese among the different cheese 247 
elaborations. Nevertheless, the ripening time was the only factor able to significantly 248 
affect most cheese properties evaluated, evolving similarly during this period as in 249 
cheeses previously described for the other macrolides studied. None of the interactions 250 
between factors analyzed were significant. 251 
4. Discussion 252 
Results herein suggest that the off-label use of macrolides in dairy goats did not 253 
significantly affect the bulk milk quality characteristics; the mean values being similar to 254 
those reported by other authors in milk from Murciano-Granadina bread goats (Blasco et 255 
al., 2016). However, this veterinary practice produces high concentrations of 256 
erythromycin, tylosin, and spiramycin, widely exceeding their respective safety levels 257 
(40, 50, and 200 µg/kg) in bulk milk obtained on the first day post-treatment making it 258 
unsuitable for human consumption, whether fresh or turned into dairy products such as 259 
cheese. In fact, the erythromycin (234.9±52.7 µg/kg), and spiramycin residues 260 
(1,539.8±469.4 µg/kg) present in goat’s milk 24 hours after treatment rendered the 261 
production of ripening cheese infeasible due to the complete inhibition of the starter 262 
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cultures activity. Cabizza et al. (2017) observed a delay of 60 minutes in the completion 263 
of the acidification process of ripened cheeses from sheep milk spiked with 100 µg/kg of 264 
oxytetracycline, in comparison to the cheese made from antibiotic-free sheep milk, due 265 
to the inhibitory effect of this substance. It should be noted that an increase in the 266 
acidification time to reach the final pH in the cheese poses a risk to consumer health as 267 
high pH values could facilitate the growth of pathogenic or undesirable microorganisms 268 
(Fox and McSweeney, 2017). In our study, the inhibition of the starter bacteria by the 269 
erythromycin and the spiramycin residues was so pronounced that the pH values of the 270 
curd remained at 6.4-6.5 along the entire production process, impeding the maturation of 271 
the cheeses. 272 
However, the presence of high concentrations of tylosin in goat’s milk collected 24 273 
hours after drug administration (198.7±57.8 µg/kg) did not affect the cheese-making 274 
processes. Nevertheless, tylosin residues were detected in AT-cheeses along the entire 275 
ripening period which could be related to the lower proteolytic activity in such cheeses 276 
containing lower FAA at the end of this period. Results herein suggest that 48.5 % of the 277 
antibiotic retained in the soft cheeses remain in the final product, the rest being degraded 278 
during maturation. The lower stability of this substance in acidic conditions (Papich and 279 
Riviere, 2001) could be related to the antibiotic losses in cheeses which presented a pH 280 
final ranging from 5.1 to 5.3. In any case, macrolides show a low protein binding ability 281 
due to their low degree of ionization. Thus, considering a mean cheese yield value for 282 
mature cheese like Tronchón of 8 (kg of milk/kg of cheese), the antibiotic retained in the 283 
cheese could represent 5-6 % of the drug initially present in the milk supply. It should be 284 
noted that the information related to the presence of macrolide residues in cheeses is 285 
practically non-existent. 286 
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After the legally established withdrawal period, seven days, erythromycin and tylosin 287 
residues were not detected in bulk milk from treated goats. Hence, considering that after 288 
48 h the residues of these substances in bulk milk are lower than the MRLs (European 289 
Commission, 2010) prescribed, the shortening of the legal withdrawal period could be 290 
considered. However, spiramycin residues can be found in milk until the eighth day of 291 
this period although being below the MRL established for this substance (200 µg/kg). 292 
These results are in agreement with those observed by other authors when studying the 293 
pharmacokinetics of macrolide antibiotics in dairy goats. Thus, while erythromycin and 294 
tylosin, given their lipophilic nature, are rapidly eliminated from the animal's organism 295 
by excretion in milk during the first hours after their systemic administration (Ambros et 296 
al., 2007; Atef et al., 2009), spiramycin requires a longer elimination period. The lower 297 
absorption rate of spiramycin could be related to its higher pKa value, possibly a result 298 
of the high degree of ionization in acidic conditions making the excretion in milk slower 299 
(DrugBank, 2018), Therefore, in spite of the fact that even after seven days, the antibiotic 300 
is detected below the MRL, further pharmacokinetic studies on spiramycin are 301 
recommended to establish its adequate withdrawal period to avoid negative implications 302 
on the consumer health. 303 
On the other hand, the absence or lower level of macrolide residues in bulk milk from 304 
goats used for cheese-making after the withdrawal period could explain the similarity of 305 
the mature Tronchón cheeses obtained with those made before initiation of the veterinary 306 
treatments. It could also explain the fact that the cheese-making processes did not differ 307 
significantly. No antibiotic residues were detected in cheeses made from milk 308 
contaminated with spyramicin obtained after a seven-day withdrawal period, evidencing 309 
the previously commented low retention capability of this substance in cheese. 310 
5. Conclusions 311 
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The off-label use of macrolides in dairy goats can result in drug residues in the milk 312 
supply if appropriate measures are not taken. The legally established minimum 313 
withdrawal period of seven days seems suitable to guarantee milk safety after the 314 
intramuscular administration of erythromycin and tylosin, without negative effects 315 
neither on the raw goat’s milk properties nor on the quality of the ripened cheese obtained. 316 
However, given the rapid elimination of these substances a shorter withdrawal period 317 
would be recommendable. Spiramycin residues can be detected in goat’s milk after the 318 
minimum safety period, thus making further studies on the behavior of this substance in 319 
dairy goats necessary to establish a more convenient withdrawal period, which also 320 
guarantees the quality of the dairy products as well as consumer safety. 321 
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Table 1 419 
Average values of parameters analysed in cheeses made at difference time after erythrimycin treatment and ANOVA F-ratio for each 420 
factor: Cheese-making (C), ripening time (R) and animal group (G). 421 
1 The manufacture of 24 h after treatment cheeses (AT-cheeses) was not possible. 422 
PT-cheeses: Pre-treatment cheeses; AW-cheeses: After withdrawal period cheeses; SE: standard error. 423 
aw: water activity; FFA: Free Fatty Acids (meq/100 g of fat); FAA: Free Amino-Acids (mg leucine/100 g cheese). 424 
*P< 0.05 indicate significant difference; ns: non-significant.425 
Parameters 
 Cheese-making (C)1  Ripening time-days (R)  Animal Group (G)  ANOVA (f-ratio) 
 PT-cheeses AW-cheeses SE  1 60 SE  1 2 SE  C R G 
Texture                 
Hardness (N)  25.36 33.88 0.63  25.29 33.95 0.63  29.45 29.79 0.63  91.64ns 94.48ns 0.15ns 
Adhesiveness (N.s)  -1.16 -1.16 0.07  -0.64 -1.68 0.07  1.19 -1.13 0.07  0.00ns 101.54ns 0.30ns 
Springiness  0.66 0.65 0.02  0.82 0.49 0.02  0.66 0.65 0.02  0.07ns 147.44ns 0.02ns 
Cohesiveness  0.49 0.49 0.02  0.72 0.27 0.02  0.48 0.50 0.02  0.01ns 445.27* 0.67ns 
Chewiness (N)  9.25 10.33 0.43  14.98 4.60 0.43  9.17 10.41 0.43  3.13ns 285.07* 4.04ns 
Colour                 
L*  89.29 87.37 0.36  89.80 86.86 0.36  87.82 88.85 0.36  14.22ns 33.05ns 4.01ns 
a*  -1.11 -0.83 0.08  -0.25 -1.69 0.08  -0.96 -0.98 0.08  6.87ns 174.44* 0.05ns 
b*  11.1 10.5 0.09  10.6 11.07 0.09  11.04 10.64 0.09  21.20ns 12.56ns 9.42ns 
Physico-chemical                 
pH  5.29 5.33 0.02  5.30 5.32 0.02  5.32 5.30 0.02  1.86ns 0.67ns 0.67ns 
aw  0.962 0.964 0.00  0.971 0.955 0.00  0.962 0.964 0.00  37.41ns 958.12* 11.69ns 
FFA  2.97 3.16 0.18  1.39 4.74 0.18  3.09 3.05 0.18  0.56ns 167.76* 0.02ns 
FAA  2.74 2.55 0.05  0.70 4.59 0.05  2.74 2.56 0.05  8.47ns 3705.53* 7.90ns 
20 
Table 2 426 
Average values of parameters analysed in cheeses made at difference time after tylosin treatment and ANOVA F-ratio for each factor: 427 
Cheese-making (C), ripening time (R) and animal group (G). 428 
PT-cheeses: Pre-treatment cheeses; AT-cheeses: After treatment cheeses; AW-cheeses: After withdrawal period cheeses; SE: standard error. 429 
aw: water activity; FFA: Free Fatty Acids (meq/100 g of fat); FAA: Free Amino-Acids (mg leucine/100 g cheese). 430 
a, b: Different letters in the same row indicate significant differences (P< 0.05); ***P< 0.001; **P< 0.01; *P< 0.05; ns: non-significant.  431 
Parameters 
 Cheese-making (C)  Ripening time-days (R)  Animal Group (G)  ANOVA (f-ratio) 
 PT-cheeses AT-cheeses AW-cheeses SE  1 60 SE  1 2 SE  C R G 
Texture                  
Hardness (N)  26.33a 38.65b 31.44ab 1.20  21.78 42.47 0.98  30.18 34.09 0.98  26.49* 222.00** 7.95ns 
Adhesiveness (N.s)  -1.40 -1.77 -1.73 0.08  -0.73 -2.53 0.07  -1.49 -1.77 0.07  5.86ns 341.12** 8.35ns 
Springiness  0.62 0.62 0.62 0.02  0.83 0.40 0.01  0.62 0.61 0.01  0.04ns 430.88** 0.18ns 
Cohesiveness  0.44 0.48 0.47 0.01  0.69 0.24 0.01  0.45 0.48 0.01  2.60ns 1528.25*** 5.96ns 
Chewiness (N)  6.35 10.91 7.85 0.89  12.57 4.17 0.73  7.98 8.76 0.73  6.74ns 66.24* 0.56ns 
Colour                  
L*  89.84 89.71 89.26 0.14  90.36 88.85 0.11  89.37 89.83 0.11  4.85ns 92.28* 8.28ns 
a*  -0.88 -0.92 -0.87 0.04  -0.25 -1.53 0.03  -0.86 -0.92 0.03  0.57ns 960.87** 2.11ns 
b*  10.41 10.49 10.79 0.06  10.00 11.12 0.05  10.67 10.47 0.05  12.57ns 289.13** 11.86ns 
Physico-chemical                  
pH  5.32 5.34 5.36 0.03  5.43 5.25 0.02  5.32 5.36 0.02  0.61ns 30.19* 0.91ns 
aw  0.962 0.963 0.963 0.00  0.969 0.957 0.00  0.962 0.964 0.00  0.61ns 225.37** 7.13ns 
FFA  2.18 2.06 2.75 0.10  1.92 2.75 0.08  2.68 1.99 0.08  14.46ns 54.85* 38.02* 
FAA  2.14b 1.89a 2.21b 0.01  0.59 3.57 0.01  2.11 2.04 0.01  179.02** 41509.12*** 22.56* 
21 
Table 3 432 
Average values of parameters analysed in cheeses made at difference time after spyramicin treatment and ANOVA F-ratio for each factor: 433 
Cheese-making (C), ripening time (R) and animal group (G).  434 
1 The manufacture of 24 h after treatment cheeses (AT-cheeses) was not possible. 435 
PT-cheeses: Pre-treatment cheeses; AW-cheeses: After withdrawal period cheeses; SE: standard error. 436 
aw: water activity; FFA: Free Fatty Acids (meq/100 g of fat); FAA: Free Amino-Acids (mg leucine/100 g cheese). 437 
Significant differences (P< 0.05); ***P< 0.001; **P< 0.01; *P< 0.05; ns: non-significant. 438 
Parameters 









1 60 SE 
 
1 2 SE 
 
C R G 
Texture                  
Hardness (N)  33.20 27.69 28.23 2.95  22.49 36.92 2.41  30.77 28.64 2.41  1.06ns 17.95ns 0.39ns 
Adhesiveness (N.s)  -1.71 -2.01 -1.20 0.11  -0.97 -2.31 0.09  -1.79 -1.49 0.09  13.60ns 108.45** 5.16ns 
Springiness  0.60 0.62 0.64 0.03  0.81 0.43 0.02  0.60 0.64 0.02  0.49ns 138.68** 1.49ns 
Cohesiveness  0.47 0.46 0.49 0.01  0.70 0.25 0.01  0.47 0.48 0.01  1.28ns 1013.63** 0.30ns 
Chewiness (N)  8.13 7.76 9.24 0.88  12.76 3.99 0.72  8.23 8.52 0.72  0.77ns 74.63* 0.08ns 
Colour                  
L*  88.79 89.47 87.22 0.55  89.92 87.07 0.45  88.22 88.77 0.45  4.37ns 19.90* 0.74ns 
a*  -0.95 -0.88 -0.94 0.02  -0.19 -1.66 0.02  -0.95 -0.90 0.02  3.35ns 3854.48*** 3.37ns 
b*  10.87 10.34 11.82 0.19  10.44 11.58 0.15  10.98 11.04 0.15  15.66ns 27.81* 0.06ns 
Physico-chemical                  
pH  5.40 5.38 5.43 0.03  5.48 5.32 0.02  5.42 5.39 0.02  0.96ns 29.47* 1.41ns 
aw  0.960 0.961 0.963 0.00  0.967 0.956 0.00  0.962 0.961 0.00  4.43ns 134.62** 1.83ns 
FFA  2.54 2.27 2.31 0.08  1.40 3.35 0.06  2.28 2.47 0.06  3.58ns 492.45** 4.78ns 
FAA  3.69 3.91 4.09 0.08  1.15 6.64 0.06  3.87 3.92 0.06  6.20ns 3604.30*** 0.34ns 
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 439 
Figure legends 440 
Fig. 1. Concentration (µg/kg) of macrolides in goat’s milk at different time after 441 
antibiotics treatment. 442 
Fig. 2. Free Amino-Acids (FAA) concentration in cheese made at different time after 443 
tylosin treatment during ripening. 444 
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*The quantification limit 
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Mean value marked with different letters for each ripening time indicate significant difference (P<0.05)
